170681-98-8

Usage

Family

Triazoles

Derivative

1,2,3-triazole

Functional Groups

a. Tributylstannyl group
b. Methyl group

Potential Applications

a. Materials Science
b. Organic Synthesis
c. Pharmaceutical Development
d. Biologically Active Compounds

Usage

Reagent for functionalization of organic molecules

Unique Features

a. Structure
b. Combination of functional groups

Value

Building block for creating new chemical entities with diverse properties and applications

Upstream product

• 16681-65-5 1-methyl-1,2,3-triazole 
• 1461-22-9 tributyltin chloride 

Downstream Products

• 1440963-66-5 N₂-(2-chloro-5-methoxy-4-(1-methyl-1H-1,2,3-triazol-5-yl)phenyl)-N₄-methyl-5-(trifluoromethyl)pyrimidine-2,4-diamine 
• 1067614-18-9 methyl 4-(1-methyl-1H-1,2,3-triazol-5-yl)benzoate 
• 202196-45-0 (4-Benzyloxy-phenyl)-(6-(3-methyl-1,2,3-triazol-4-yl)-quinazolin-4-yl)-amine 

Relevant academic research and scientific papers

HEXONE GLUCOKINASE INHIBITOR AND USE THEREOF

The present invention relates to the technical field of pharmaceuticals, and in particular to a ketohexokinase inhibitor compound, a pharmaceutically acceptable salt, an ester or a stereoisomer thereof; a pharmaceutical composition and formulation containing the compound, the pharmaceutically acceptable salt, the ester or the stereoisomer thereof; a method for preparing the compound, the pharmaceutically acceptable salt, the ester or the stereoisomer thereof; and use of the compound, the pharmaceutically acceptable salt, the ester or the stereoisomer thereof in the manufacture of a medicament for treating and/or preventing KHK-mediated diseases and related conditions.

METHOD OF CONTROLLING LACTATE PRODUCTION WITH PIPERDINE-DIONE DERIVATIVES

The invention provides novel compounds having the general formula: and tautomers and pharmaceutically acceptable salts thereof, wherein A1, A2, A3, A4, R1, R4, R5, R6, R7 and R8 are as defined herein, compositions including the compounds and methods of using the compounds.

PIPERIDINE-DIONE DERIVATIVES

The invention provides novel compounds having the general formula (I) and tautomers and pharmaceutically acceptable salts thereof, wherein A1, A2, A3, A4, R1, R4, R5, R6, R7 and R8 are as defined herein, compositions including the compounds and methods of using the compounds.

1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS

The present invention relates to l H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as AMPA-receptor ligands, in particular for the treatment of epilepsy or schizophrenia, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) and combinations comprising compounds of formula (I) are disclosed.